Literature DB >> 7998422

Development of a candidate vaccine against Ross River virus infection.

S Yu1, J G Aaskov.   

Abstract

Ross River virus is a mosquito-borne alphavirus which causes several thousand cases of arthritis (epidemic polyarthritis) each year. In this study, binary ethylenimine (BEI) was used to destroy the infectivity of this virus without abolishing the antigenicity or immunogenicity of the virion. Mice immunized intramuscularly with BEI-inactivated virus, with or without Alhydrogel adjuvant, produced antibody which neutralized Ross River virus in vitro, and the mice also failed to develop viraemia when challenged intravenously with live virus. Serum neutralization and in vivo protection were greatest when BEI-inactivated virus was administered without adjuvant.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7998422     DOI： 10.1016/0264-410x(94)90182-1

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  6 in total

1.  Alphavirus-specific cytotoxic T lymphocytes recognize a cross-reactive epitope from the capsid protein and can eliminate virus from persistently infected macrophages.

Authors:  M L Linn; L Mateo; J Gardner; A Suhrbier
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

2.  An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial.

Authors:  Nina Wressnigg; Maikel V W van der Velden; Daniel Portsmouth; Wolfgang Draxler; Maria O'Rourke; Peter Richmond; Stephen Hall; William J H McBride; Andrew Redfern; John Aaskov; P Noel Barrett; Gerald Aichinger
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

Review 3.  Ross River virus transmission, infection, and disease: a cross-disciplinary review.

Authors:  D Harley; A Sleigh; S Ritchie
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

4.  Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling.

Authors:  Charalambos D Partidos; James Weger; Joseph Brewoo; Robert Seymour; Erin M Borland; Jeremy P Ledermann; Ann M Powers; Scott C Weaver; Dan T Stinchcomb; Jorge E Osorio
Journal:  Vaccine       Date:  2011-02-05       Impact factor: 3.641

5.  Chikungunya virus arthritis in adult wild-type mice.

Authors:  Joy Gardner; Itaru Anraku; Thuy T Le; Thibaut Larcher; Lee Major; Pierre Roques; Wayne A Schroder; Stephen Higgs; Andreas Suhrbier
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

Review 6.  Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape.

Authors:  Anthony Torres-Ruesta; Rhonda Sin-Ling Chee; Lisa F P Ng
Journal:  Microorganisms       Date:  2021-04-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.